CINECA IRIS Institutional Research Information System

RAGUSA, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.120
AS - Asia 2.088
EU - Europa 1.896
SA - Sud America 469
AF - Africa 124
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 3
Totale 8.708
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.024
IT - Italia 797
SG - Singapore 656
CN - Cina 591
BR - Brasile 391
HK - Hong Kong 374
SE - Svezia 346
DE - Germania 181
VN - Vietnam 159
BG - Bulgaria 110
GB - Regno Unito 93
RU - Federazione Russa 76
FR - Francia 65
IN - India 56
NL - Olanda 56
CA - Canada 50
FI - Finlandia 50
IQ - Iraq 43
CI - Costa d'Avorio 41
TR - Turchia 38
AR - Argentina 29
BD - Bangladesh 29
JP - Giappone 28
MX - Messico 27
PL - Polonia 25
AT - Austria 22
SN - Senegal 21
KR - Corea 20
NG - Nigeria 20
ES - Italia 16
EC - Ecuador 15
ZA - Sudafrica 14
CO - Colombia 12
SA - Arabia Saudita 12
UA - Ucraina 12
CZ - Repubblica Ceca 9
ID - Indonesia 9
PY - Paraguay 9
IE - Irlanda 8
PH - Filippine 8
JO - Giordania 7
LT - Lituania 7
MA - Marocco 7
UZ - Uzbekistan 7
AU - Australia 6
AE - Emirati Arabi Uniti 5
CH - Svizzera 5
IR - Iran 5
PK - Pakistan 5
PS - Palestinian Territory 5
UY - Uruguay 5
BE - Belgio 4
BY - Bielorussia 4
CR - Costa Rica 4
IL - Israele 4
KE - Kenya 4
TN - Tunisia 4
VE - Venezuela 4
AL - Albania 3
CU - Cuba 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
HN - Honduras 3
KZ - Kazakistan 3
MY - Malesia 3
BB - Barbados 2
BH - Bahrain 2
BJ - Benin 2
BN - Brunei Darussalam 2
CL - Cile 2
EG - Egitto 2
ET - Etiopia 2
EU - Europa 2
GE - Georgia 2
GT - Guatemala 2
NP - Nepal 2
OM - Oman 2
PE - Perù 2
RO - Romania 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AM - Armenia 1
CY - Cipro 1
DK - Danimarca 1
EE - Estonia 1
FJ - Figi 1
GA - Gabon 1
GR - Grecia 1
KG - Kirghizistan 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
ML - Mali 1
NZ - Nuova Zelanda 1
QA - Qatar 1
RS - Serbia 1
SC - Seychelles 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
Totale 8.706
Salva come PNG Salva come JPEG
Città #
Ashburn 534
Dallas 520
Fairfield 400
Singapore 376
Hong Kong 368
Santa Clara 365
Woodbridge 205
Chandler 179
Milan 179
Seattle 174
Shanghai 173
Pisa 171
Cambridge 149
Houston 144
Wilmington 132
Serra 127
Sofia 110
New York 99
Los Angeles 93
Beijing 85
Munich 78
Boardman 72
Princeton 72
Ann Arbor 58
London 47
Lawrence 46
Florence 44
Medford 42
Abidjan 41
Rome 40
Frankfurt am Main 35
Hefei 35
Redondo Beach 34
São Paulo 29
Dong Ket 27
Ho Chi Minh City 27
Boulder 26
Buffalo 25
Tokyo 24
Turku 24
Redwood City 23
San Diego 23
Istanbul 22
Dakar 21
Bremen 20
Seoul 20
Des Moines 19
Fuzhou 19
Ottawa 19
Paris 19
Warsaw 19
Helsinki 18
Lagos 18
Sulaymaniyah 18
Nuremberg 17
Nanjing 16
Ogden 16
Livorno 15
Rio de Janeiro 14
Vienna 14
Carrara 13
Dearborn 12
Phoenix 12
Washington 12
Amsterdam 11
Baghdad 11
Hanoi 11
Johannesburg 11
Norwalk 11
Brasília 10
Changsha 10
Düsseldorf 10
Guangzhou 10
Hyderabad 10
Denver 9
Montreal 9
Quanzhou 9
Brooklyn 8
Dublin 8
Lauterbourg 8
Toronto 8
Amman 7
Belo Horizonte 7
Boston 7
Chengdu 7
Chennai 7
Council Bluffs 7
Dhaka 7
Tashkent 7
Tianjin 7
Cascina 6
Chicago 6
Da Nang 6
Dammam 6
Lappeenranta 6
Lucca 6
Quito 6
Shenyang 6
Wuhan 6
Asunción 5
Totale 6.114
Salva come PNG Salva come JPEG
Nome #
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 229
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo 211
Molecular testing in the diagnosis of differentiated thyroid carcinomas 205
Sunitinib in the treatment of thyroid cancer 197
Hashimotos’ thyroiditis: Epidemiology, pathogenesis, clinic and therapy 197
The aggregation between AITD with rheumatologic, or dermatologic, autoimmune diseases 183
Oral L-thyroxine liquid versus tablet in patients submitted to total thyroidectomy for thyroid cancer (without malabsorption): A prospective study 182
Novel therapies for thyroid autoimmune diseases: An update 172
Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer 170
Induction of Th1 chemokine secretion in dermal fibroblasts by vanadium pentoxide 166
New insight in endocrine-related adverse events associated to immune checkpoint blockade 163
Cytokines as Targets of Novel Therapies for Graves’ Ophthalmopathy 156
The association of other autoimmune diseases in patients with Graves’ disease (with or without ophthalmopathy): Review of the literature and report of a large series 154
THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors 153
Differential modulation by vanadium pentoxide of the secretion of CXCL8 and CXCL11 chemokines in thyroid cells 150
Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy 150
Graves’ disease: Epidemiology, genetic and environmental risk factors and viruses 150
Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update 149
Immunomodulation of CXCL10 secretion by hepatitis C virus: Could CXCL10 be a prognostic marker of chronic hepatitis C? 149
Novel treatments for anaplastic thyroid carcinoma 146
Vanadium pentoxide induces the secretion of CXCL9 and CXCL10 chemokines in thyroid cells 145
Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture 144
Recent advances in precision medicine for the treatment of anaplastic thyroid cancer 142
Novel treatment options for anaplastic thyroid cancer 140
Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration 139
CXCL8 and CXCL11 chemokine secretion in dermal fibroblasts is differentially modulated by vanadium pentoxide 138
The Stability of TSH, and Thyroid Hormones, in Patients Treated With Tablet, or Liquid Levo-Thyroxine 138
Myo-inositol in autoimmune thyroiditis, and hypothyroidism 136
Immune and inflammatory cells in thyroid cancer microenvironment 136
The protective effect of myo-inositol on human thyrocytes 133
Nutraceuticals in thyroidology: A review of in vitro, and in vivo animal studies 133
Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy 131
Autoimmune endocrine dysfunctions associated with cancer immunotherapies 128
Molecular features of aggressive thyroid cancer 125
Circulating CXCL10 is increased in non-segmental vitiligo, in presence or absence of autoimmune thyroiditis 125
Precision Medicine in Autoimmune Thyroiditis and Hypothyroidism 125
Chemokines in thyroid autoimmunity 122
Thyroid Autoimmunity and SARS-CoV-2 Infection 122
Molecular targets of tyrosine kinase inhibitors in thyroid cancer 121
Chemokines in hyperthyroidism 119
Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies 119
null 115
Thyroid Metastasis from Primary Breast Cancer 111
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 110
Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer 108
Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases 105
Lactose intolerance and levothyroxine malabsorption: a review of the literature and report of a series of patients treated with liquid L-T4 without lactose 103
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 103
Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin 102
Liquid L-T4 therapy in hypothyroid patients with gastric diseases, an observational study 98
Antineoplastic effect of doxorubizen in vitro in continuous and primary human anaplastic thyroid cancer cells 98
Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer 97
Precision Medicine in Graves’ Disease and Ophthalmopathy 97
Graves' disease induced by IFN-β1a therapy: A case report, review of literature and new insights into the pathogenesis 96
Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies 95
Hypothyroidism and metabolic cardiovascular disease 93
Teprotumumab for the treatment of thyroid eye disease 93
Endocrine disruptors and thyroid autoimmunity 93
L-T4 Therapy in Enteric Malabsorptive Disorders 92
Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN-ALK Fusion In Vitro 91
Simultaneous Occurrence of Medullary Thyroid Carcinoma and Papillary Thyroid Carcinoma: A Case Series with Literature Review 90
Evaluating vandetanib in the treatment of medullary thyroid cancer: Patient-reported outcomes 90
null 87
Thyroid autoimmunity and SARS-CoV-2 infection: Report of a large Italian series 75
null 75
null 73
Graves' Disease Following SARS-CoV-2 Vaccination: A Systematic Review 72
Myoinositol in Autoimmune Thyroiditis 62
Thyroid autoimmune disorders and cancer 57
Th1 chemokines in autoimmune endocrine disorders 52
Psoriasis, Psoriatic Arthritis, and Thyroid Autoimmunity 32
Autoimmune Thyroid Diseases and Epigenetics 28
IP-10 in occupational asthma: review of the literature and case-control study 24
Th1 chemokines in ulcerative colitis 24
Dermatomyositis and MIG 24
MIG chemokine in systemic sclerosis. MIG in Systemic sclerosis 23
Mesothelioma and interferon-γ-dependent chemokine IP-10 22
Sarcoidosis and Th1 chemokines 22
Sarcoidosis and the Th1 chemokine MIG 18
Totale 9.043
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.369
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.369
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021290 0 0 0 0 0 0 18 53 34 61 28 96
2021/2022715 13 14 28 47 109 92 32 33 67 59 56 165
2022/2023770 118 106 67 37 68 92 34 46 122 5 62 13
2023/2024836 67 78 121 97 120 135 55 24 12 17 38 72
2024/20252.664 119 72 72 140 259 310 259 126 153 287 311 556
2025/20262.172 260 388 559 380 321 264 0 0 0 0 0 0
Totale 9.043